Detection of circulating tumour cell clusters in human glioblastoma

Krol, Ilona; Castro-Giner, Francesc; Maurer, Martina; Gkountela, Sofia; Szczerba, Barbara M.; Scherrer, Ramona; Coleman, Niamh; Carreira, Suzanne; Bachmann, Felix; Anderson, Stephanie; Engelhardt, Marc; Lane, Heidi A.; Evans, T.R. Jeffry; Plummer, Ruth; Kristeleit, Rebecca; Lopez, Juanita; Aceto, Nicola

doi:10.1038/s41416-018-0186-7

Cited by 116 publications

(120 citation statements)

References 14 publications

Supporting

Mentioning

118

Contrasting

Order By: Relevance

“…Cancer cells that are detached from the primary tumor site and entered the bloodstream are categorized as CTCs [143]. The implication of CTCs is well established in tumor cell dormancy, as a major cause of metastatic outgrowth, multi drug resistance (MDR) and cancer relapse [144].…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Tumor microenvironment complexity and therapeutic implications at a glance

et al. 2020

View full text Add to dashboard Cite

The dynamic interactions of cancer cells with their microenvironment consisting of stromal cells (cellular part) and extracellular matrix (ECM) components (non-cellular) is essential to stimulate the heterogeneity of cancer cell, clonal evolution and to increase the multidrug resistance ending in cancer cell progression and metastasis. The reciprocal cell-cell/ECM interaction and tumor cell hijacking of non-malignant cells force stromal cells to lose their function and acquire new phenotypes that promote development and invasion of tumor cells. Understanding the underlying cellular and molecular mechanisms governing these interactions can be used as a novel strategy to indirectly disrupt cancer cell interplay and contribute to the development of efficient and safe therapeutic strategies to fight cancer. Furthermore, the tumor-derived circulating materials can also be used as cancer diagnostic tools to precisely predict and monitor the outcome of therapy. This review evaluates such potentials in various advanced cancer models, with a focus on 3D systems as well as lab-on-chip devices.

show abstract

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Tumor microenvironment complexity and therapeutic implications at a glance

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The system is fully agnostic regarding upstream enrichment methods handling large numbers of contaminating cells (e.g., 50,000 per sample) and does not require sample volume reduction. CellCelector™ has been successfully used downstream of various CTC enrichment techniques: (i) positive immune‐magnetic: CellSearch® , Isoflux™ , Illumina MagSweeper™ ; (ii) negative immune‐magnetic: Dynal® MPC‐S , RosetteSep CD45 ; (iii) density gradient centrifugation ; or (iv) size‐based separation: Parsortix™ .…”

Section: Als Cell Celector™mentioning

confidence: 99%

“…Variable capillary sizes allow for isolation of not only individual single cells but also multicellular CTC clusters , spheroids/organoids, or even working with tissue sections (FFPE/fresh frozen). Utilizing multiple picking steps (1st step picking of clusters, 2nd step picking of individual cells from the destination well of the 1st step after dissociation of the cluster) allows to study the heterogeneity of clusters on single cell level which would be otherwise impossible.…”

Section: Als Cell Celector™mentioning

confidence: 99%

Automated rare single cell picking with the ALS cellcelector™

Nelep¹,

Eberhardt²

2018

Cytometry Pt A

View full text Add to dashboard Cite

Molecular analysis of rare single cells like circulating tumor cells (CTCs) from whole blood patient samples bears multiple challenges. One of those challenges is the efficient and ideally loss-free isolation of CTCs over contaminating white and red blood cells. While there is a multitude of commercial and non-commercial systems available for the enrichment of CTCs their cell output does not deliver the purity most molecular analysis methods require. Here we describe the ALS CellCelector™ which can solve this challenge allowing the retrieval of 100% pure single CTCs from blood processed by different upstream enrichment techniques. It is a multifunctional, extremely flexible system for automated screening of cell culture plates, Petri dishes, and microscope slides. Fixed or live single cells or multicellular clusters detected during screening can be picked out of those plates automatically. The complete scan and picking process is fully documented hence allowing highest standardization and reproducibility of all processes. Use of CellCelector allowed the isolation of pure single tumor cells or clusters from liquid biopsies of breast, prostate, ovarian, colorectal, lung, and brain cancers for their subsequent molecular analysis. © 2018 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of International Society for Advancement of Cytometry.

show abstract

“…However, due in part to the blood‐brain barrier, the investigation of CTCs in brain cancers is in its infancy. CTCs have been detected for human glioblastoma, the most common and a highly aggressive and invasive brain cancer . CTCs have been found to be significantly associated with the prognosis of patients with brain cancer, with >5 times the CTC count noted among patients with progressive versus stable glioblastoma, and CTCs with a mesenchymal signature, a subtype correlated with tumor resistance to radiotherapy and chemotherapy, have been detected and reported to demonstrate promise for prognosis and treatment guidance …”

Section: Introductionmentioning

confidence: 99%

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Jin

Chen

Lan³

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

The process of metastasis is characterized by the shedding of tumor cells into the bloodstream, where they are transported to other parts of the body to seed new tumors. These cells, known as circulating tumor cells (CTCs), have the potential to reveal much about an individual cancer case, and theoretically can aid in the prediction of outcomes and design of precision treatments. Recent advances in technology now allow for the robust and reproducible characterization of CTCs from a simple blood draw. Both the number of circulating cells and important molecular characteristics correlated with clinical phenotypes such as drug resistance can be obtained and used for real‐time prognostic analysis. Molecular characterization can provide a snapshot of the activity of the main tumor (serving as a “liquid biopsy”) and early warnings concerning changes such as the development of resistance, and aid in predicting the efficacy of different therapeutic approaches for treatment optimization. Herein, the authors review the current clinical use of CTCs as prognostic biomarkers for several different cancers. The quantification of CTCs can lead to more accurate staging and decision making regarding options such as adjuvant chemotherapy.

show abstract

Detection of circulating tumour cell clusters in human glioblastoma

Cited by 116 publications

References 14 publications

Tumor microenvironment complexity and therapeutic implications at a glance

Tumor microenvironment complexity and therapeutic implications at a glance

Automated rare single cell picking with the ALS cellcelector™

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Contact Info

Product

Resources

About